[
    [
        {
            "time": "2023-10-15",
            "original_text": "Investigational 2.0 mg dose of Ozempic速 (semaglutide) demonstrates superior reductions in blood sugar vs Ozempic速 1.0 mg in adults with type 2 diabetes in a phase 3 trial",
            "features": {
                "keywords": [
                    "Ozempic",
                    "semaglutide",
                    "superior reductions",
                    "blood sugar",
                    "type 2 diabetes",
                    "phase 3 trial"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Investigational 2.0 mg dose of Ozempic速 (semaglutide) demonstrates superior reductions in blood sugar vs Ozempic速 1.0 mg in adults with type 2 diabetes in a phase 3 trial",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]